The round was led by Savitr Capital and Hayfin Capital Management. This significant funding will fuel the continued expansion of Glytec's platform, including its flagship Glucommander® SaaS solution, accelerate the development of innovative new technologies to address the growing global health crisis of diabetes and related co-morbidities, and support the continued rapid response to upcoming CMS quality measures that will hold health systems accountable for inpatient glycemic control.

Glytec's industry-leading technology platform, trusted by over 400 hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing hospital length of stay, and optimizing clinical workflows. It's flagship product, Glucommander® -- the first-ever FDA-cleared cloud-based insulin management software -- integrates seamlessly with EMRs, providing advanced clinical decision support, workflow alerts, patient monitoring, and AI-driven analytics. Supported by over 100 patents and 100 clinical and peer-reviewed publications, Glytec is dedicated to improving metabolic care from hospital to home.